Your Messages Inbox
Your Article Summary
See Latest ArticlesNabi Biopharmaceuticals Announces Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 08/07/09
Nabi Biopharmaceuticals announced that it has signed a definitive agreement for the sale of PentaStaph and related assets to GlaxoSmithKline for a total consideration of up to $46 million. Under the terms of the agreement, Nabi will receive an initial cash payment of $20 million when the transaction closes plus an additional $26 million contingent upon four milestone accomplishments. The sale is subject to satisfaction of certain customary closing conditions by the buyer and seller prior to closing. Nabi anticipates closing the sale before year–end 2009 and completing the milestones within the next 18 months.
Today in Financial Reports...keeping you current
Receive free subspecialty "5-minute updates" via email
Abbott Declares 344th Consecutive Quarterly Dividend
Abbott, 12/15/09
Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering
Dendreon Coproration, 12/15/09
Pre-Budget Report response - GSK comments on patent box
GlaxoSmithKline, 12/11/09
Article Search
Sponsor